Home / Recalls / Pfizer Inc. / D-0754-2022

D-0754-2022 Class II Terminated

Recalled by Pfizer Inc. — New York, NY

Recall Details

Product Type
Drugs
Report Date
April 13, 2022
Initiation Date
March 21, 2022
Termination Date
August 28, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
53 bottles

Product Description

Accuretic (quinapril HCl/hydrochlorothiazide) Tablets, 10 mg/12.5 mg*, 90 Tablets bottles, Rx Only, Distributed by: Parke-Davis, Division of Pfizer Inc, NY, NY 10017, Made in Germany, NDC 0071-3112-23.

Reason for Recall

CGMP Deviations: N-nitroso-quinapril and N-nitroso-hydrochlorothiazide impurity above the acceptable daily intake limit.

Distribution Pattern

Nationwide

Code Information

Lot FG5379; Exp. 08/2024

Other recalls by Pfizer Inc.

  • D-0591-2025 Class II — Vial Label: 8.4% Sodium Bicarbonate Injection, USP, 50mEq/50 mL (1 mEq/mL), Rx o (August 4, 2025)
  • D-0590-2025 Class II — Vial Label: Epinephrine Injection, USP, 1mg/10mL (0.1 mg/mL), Rx only, Distribut (August 4, 2025)
  • D-0575-2025 Class II — Levoxyl (levothyroxine sodium tablets, USP), 50 mcg, 100-count bottle, Rx only, (July 29, 2025)
  • D-0545-2025 Class II — Bicillin L-A (penicillin G benzathine injectable suspension), 2,400,000 units pe (July 10, 2025)
  • D-0544-2025 Class II — Bicillin L-A (penicllin G benzathine injectable suspension), 1,200,000 units per (July 10, 2025)
  • D-0489-2025 Class II — DOBUTamine Injection, USP, 250 mg/20 mL (12.5 mg/mL), 20 mL per Single-dose Vial (May 28, 2025)
  • D-0565-2024 Class II — Labetalol Hydrochloride Injection, USP, 20 mg/4 mL (5 mg/mL), 4 mL Single-dose C (May 20, 2024)
  • D-0564-2024 Class II — Buprenorphine Hydrochloride Injection, 0.3 mg base/mL, 1 mL Single-dose Carpujec (May 20, 2024)
  • D-0261-2024 Class I — Bleomycin for Injection, USP, 15 units per vial, 1 single dose glass fliptop via (December 21, 2023)
  • D-0233-2024 Class I — 4.2% Sodium Bicarbonate Injection, USP 5 mEq/10 mL (0.5 mEq/mL), Glass ABBOJECT (December 21, 2023)